Actions: Gelofusine is a colloidal plasma volume substitute. When used in the treatment of hypovolaemia it produces a significant increase in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery. The half-life of Gelofusine is about 4 hours, with the majority of the dose administered being eliminated by renal excretion within 24 hours.

Indications: As a plasma volume substitute in cats, dogs and horses in the initial management of hypovolaemic shock due to, for example, haemorrhage, acute trauma or surgery, burns, sepsis, peritonitis or crush injury.